PARP plays a critical role in DNA repair and has been studied as therapy for patients with breast cancer who harbor germlineBRCA1orBRCA2variants.
Evidence (olaparib): TheOlympiADtrial (NCT02000622) was a randomized, open-label, phase III trial that randomly assigned 302 patients, in a 2:1 ratio, to receive olaparib (300 mg bid) or standard therapy (either single-agent capecitabine, eribulin, or vinorelbine).[86] All patients had received anthracycline and taxane previously in either the adjuvant or metastatic setting, and those with hormone receptorâ€“positive disease had also received endocrine therapy previously.Median PFS was significantly longer in the olaparib group than in the standard therapy group (7.0 months vs.